论文部分内容阅读
目的:研究肽基精氨酸脱亚胺酸4(PADI4)在不同类型卵巢癌组织中的表达及与临床病理之间的关系。方法:用免疫组织化学法检测和定量分析PADI4在不同类型卵巢癌组织中的表达;用RT-PCR和蛋白质印迹法比较卵巢腺癌(8例)和卵巢囊腺瘤(5例)中的表达水平。结果:PADI4在浆液性囊腺癌(53例,阳性率100%)、黏液性囊腺癌(19例,100%)、子宫内膜型囊腺癌(23例,100%)、透明细胞癌(6例,100%)、内胚窦癌(6例,100%)、鳞状细胞癌(6例,100%)、转移性腺癌(6例,100%)、印戎细胞癌(6例,100%)、无性细胞癌(6例,100%)、生殖细胞癌(6例,100%)和未成熟畸胎瘤(6例,100%)中高表达,但在恶性颗粒细胞瘤(6例)、恶性卵泡膜细胞瘤(6例)以及正常卵巢组织(10例)无表达。在浆液性囊腺癌、黏液性囊腺癌和子宫内膜性囊腺癌中,PADI4表达水平与年龄和临床分期T显著正相关,P<0.01;RT-PCR和蛋白质印迹法证实,PADI4在卵巢腺癌的表达量显著高于在卵巢囊腺瘤中的表达,P=0.001。结论:PADI4可能在多种类恶性卵巢瘤病变过程中起着重要作用。
Objective: To study the expression of peptidyl arginine-4 (PADI4) in different types of ovarian cancer and its relationship with clinicopathology. Methods: The expression of PADI4 was detected by immunohistochemistry in different types of ovarian cancer tissues. The expression of PADI4 in ovarian adenocarcinoma (8 cases) and ovarian cystadenoma (5 cases) was compared by RT-PCR and Western blotting Level. Results: The positive rates of PADI4 in serous cystadenocarcinoma (53 cases, 100%), mucinous cystadenocarcinoma (19 cases, 100%), endometrial cystadenocarcinoma (23 cases, 100%), clear cell carcinoma (6 cases, 100%), endodermal carcinoma (6 cases, 100%), squamous cell carcinoma (6 cases, 100%), metastatic adenocarcinoma (6 cases, 100% , 100%), asexual cell carcinoma (6 cases, 100%), germ cell carcinoma (6 cases, 100%) and immature teratoma (6 cases, 100% Cases), malignant mecaocytoma (6 cases) and normal ovarian tissue (10 cases) were not expressed. In serous cystadenocarcinoma, mucinous cystadenocarcinoma and endometrial cystadenocarcinoma, PADI4 expression level was significantly and positively correlated with age and clinical stage T, P <0.01; RT-PCR and Western blotting confirmed that PADI4 was The expression of ovarian adenocarcinoma was significantly higher than that in ovarian cystadenoma (P = 0.001). Conclusion: PADI4 may play an important role in the pathogenesis of various malignant ovarian tumors.